2020
A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Ileana Dumbrava E, Suarez-Almazor M, Painter J, Johanns T, Dougan M, Cappelli L, Bingham C, Wang Y, Gupta S, Warner B, Rahma O, Naidoo J, Ott P, Hafler D, Kluger H, Khosroshahi A, Katsumoto T, Kummar S, Sharon E, Tawbi H. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). Journal Of Clinical Oncology 2020, 38: tps3158-tps3158. DOI: 10.1200/jco.2020.38.15_suppl.tps3158.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAnti-PD-1/PD-L1 antibodiesPhase Ib studyPD-L1 antibodiesAutoimmune disordersAdvanced malignanciesDisease-specific cohortsAdverse eventsIb studyPre-existing autoimmune disordersImpact of nivolumabRisk of flareKey secondary endpointSerious adverse eventsBest objective responseDose-limiting toxicityInflammatory bowel diseaseSeverity IndexSystemic lupus erythematosusAnti-PD1 antibodyClinical Trials NetworkTissue-based biomarkersSpecific eligibility criteriaICI therapyCheckpoint inhibitors
2014
Pregnancy‐related issues in women with systemic lupus erythematosus
Singh AG, Chowdhary VR. Pregnancy‐related issues in women with systemic lupus erythematosus. International Journal Of Rheumatic Diseases 2014, 18: 172-181. PMID: 25545844, DOI: 10.1111/1756-185x.12524.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusActive diseaseLupus erythematosusPregnancy lossHigh-risk obstetric clinicRisk of flareAdverse pregnancy outcomesCongenital heart blockPregnancy-related issuesRecurrent pregnancy lossIntrauterine growth retardationPersonalized treatment strategiesTime of conceptionMaternal hypertensionActive nephritisAntiphospholipid antibodiesFetal outcomesNeonatal lupusPregnant patientsPreterm deliveryPregnancy outcomesPreterm birthHeart blockNeonatal mortalityAdverse outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply